219 related articles for article (PubMed ID: 21304001)
1. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
Rudin CM; Poirier JT; Senzer NN; Stephenson J; Loesch D; Burroughs KD; Reddy PS; Hann CL; Hallenbeck PL
Clin Cancer Res; 2011 Feb; 17(4):888-95. PubMed ID: 21304001
[TBL] [Abstract][Full Text] [Related]
2. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
Reddy PS; Burroughs KD; Hales LM; Ganesh S; Jones BH; Idamakanti N; Hay C; Li SS; Skele KL; Vasko AJ; Yang J; Watkins DN; Rudin CM; Hallenbeck PL
J Natl Cancer Inst; 2007 Nov; 99(21):1623-33. PubMed ID: 17971529
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.
Poirier JT; Reddy PS; Idamakanti N; Li SS; Stump KL; Burroughs KD; Hallenbeck PL; Rudin CM
J Gen Virol; 2012 Dec; 93(Pt 12):2606-2613. PubMed ID: 22971818
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Seneca Valley Virus: past perspectives and future directions.
Burke MJ
Oncolytic Virother; 2016; 5():81-9. PubMed ID: 27660749
[TBL] [Abstract][Full Text] [Related]
5. A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma.
Zhao Z; Cao L; Sun Z; Liu W; Li X; Fang K; Shang X; Hu J; Chen H; Lou Z; Qian P
J Virol; 2023 May; 97(5):e0045923. PubMed ID: 37097154
[TBL] [Abstract][Full Text] [Related]
6. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.
Miles LA; Burga LN; Gardner EE; Bostina M; Poirier JT; Rudin CM
J Clin Invest; 2017 Aug; 127(8):2957-2967. PubMed ID: 28650343
[TBL] [Abstract][Full Text] [Related]
7. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.
Poirier JT; Dobromilskaya I; Moriarty WF; Peacock CD; Hann CL; Rudin CM
J Natl Cancer Inst; 2013 Jul; 105(14):1059-65. PubMed ID: 23739064
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
9. Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage.
Qian S; Fan W; Liu T; Wu M; Zhang H; Cui X; Zhou Y; Hu J; Wei S; Chen H; Li X; Qian P
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566380
[TBL] [Abstract][Full Text] [Related]
10. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.
Burke MJ; Ahern C; Weigel BJ; Poirier JT; Rudin CM; Chen Y; Cripe TP; Bernhardt MB; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):743-50. PubMed ID: 25307519
[TBL] [Abstract][Full Text] [Related]
12. Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.
Venkataraman S; Reddy SP; Loo J; Idamakanti N; Hallenbeck PL; Reddy VS
Structure; 2008 Oct; 16(10):1555-61. PubMed ID: 18940610
[TBL] [Abstract][Full Text] [Related]
13. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
[TBL] [Abstract][Full Text] [Related]
14. Cryo-Electron Microscopy Structure of Seneca Valley Virus Procapsid.
Strauss M; Jayawardena N; Sun E; Easingwood RA; Burga LN; Bostina M
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263256
[TBL] [Abstract][Full Text] [Related]
15. Identification of a conserved neutralizing epitope in Seneca Valley virus VP2 protein: new insight for epitope vaccine designment.
Wen W; Chen X; Lv Q; Chen H; Qian P; Li X
Virol J; 2022 Apr; 19(1):65. PubMed ID: 35410270
[TBL] [Abstract][Full Text] [Related]
16. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
Kennedy EM; Denslow A; Hewett J; Kong L; De Almeida A; Bryant JD; Lee JS; Jacques J; Feau S; Hayes M; McMichael EL; Wambua D; Farkaly T; Rahmeh AA; Herschelman L; Douglas D; Spinale J; Adhikari S; Deterling J; Scott M; Haines BB; Finer MH; Ashburn TT; Quéva C; Lerner L
Nat Commun; 2022 Oct; 13(1):5907. PubMed ID: 36207308
[TBL] [Abstract][Full Text] [Related]
17. Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy.
Miles LA; Brennen WN; Rudin CM; Poirier JT
PLoS One; 2015; 10(6):e0129103. PubMed ID: 26069962
[TBL] [Abstract][Full Text] [Related]
18. Seneca Valley Virus 2C and 3C
Liu T; Li X; Wu M; Qin L; Chen H; Qian P
Front Microbiol; 2019; 10():1202. PubMed ID: 31191506
[TBL] [Abstract][Full Text] [Related]
19. Crystallization and preliminary X-ray diffraction studies of Seneca Valley virus-001, a new member of the Picornaviridae family.
Venkataraman S; Reddy SP; Loo J; Idamakanti N; Hallenbeck PL; Reddy VS
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 Apr; 64(Pt 4):293-6. PubMed ID: 18391430
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of a Seneca Valley virus thermostable mutant.
Jayawardena N; McCarthy C; Wang I; Waqqar S; Burga LN; Strauss M; Bostina M
Virology; 2022 Oct; 575():74-82. PubMed ID: 36084546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
